HealthEquity Q2 FY2027业绩超预期并上调全年指引，但指引上调幅度已被卖方预期

----- 0001428336-26-000040.txt -----
0001428336-26-000040.txt : 20260827
0001428336-26-000040.hdr.sgml : 20260827
20260827080252
ACCESSION NUMBER: 0001428336-26-000040
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 12
CONFORMED PERIOD OF REPORT: 20260827
ITEM INFORMATION: Results of Operations and Financial Condition
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260827
DATE AS OF CHANGE: 20260827
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: HEALTHEQUITY, INC.
CENTRAL INDEX KEY: 0001428336
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389]
ORGANIZATION NAME: 07 Trade & Services
EIN: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0131
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36568
FILM NUMBER: 261325150
BUSINESS ADDRESS:
STREET 1: 15 WEST SCENIC POINTE DRIVE
STREET 2: SUITE 100
CITY: DRAPER
STATE: UT
ZIP: 84020
BUSINESS PHONE: 801-727-1000
MAIL ADDRESS:
STREET 1: 15 WEST SCENIC POINTE DRIVE
STREET 2: SUITE 100
CITY: DRAPER
STATE: UT
ZIP: 84020
FORMER COMPANY:
FORMER CONFORMED NAME: HEALTHEQUITY INC
DATE OF NAME CHANGE: 20080227
8-K
1
hqy-20260827.htm
8-K
hqy-20260827
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
August 27, 2026
HEALTHEQUITY, INC.
Delaware
001-36568
52-2383166
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)
15 West Scenic Pointe Drive
Suite 100
Draper
,
Utah
84020
(
801
)
727-1000
(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
HQY
The NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition
On August 27, 2026, HealthEquity, Inc. issued a press release attached as Exhibit 99.1 to this current report on Form 8-K.
The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press release issued by HealthEquity, Inc. dated August 27, 2026, announcing financial results for its fiscal quarter ended July 31, 2026.
104
Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTHEQUITY, INC.
Date: August 27, 2026
By:
/s/ James Lucania
Name:
James Lucania
Title:
Executive Vice President and Chief Financial Officer
EX-99.1
2
hqyearningsrelease-fy27q2.htm
EX-99.1
Document
HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results
Highlights of the second quarter include:
•
Net income increased
10%
to
$65.6 million
, and net income margin increased to
19%
from
18%
last year.
•
Adjusted EBITDA increased
11%
to
$167.0 million
, and Adjusted EBITDA margin increased to
48%
from
46%
last year.
•
Revenue increased
8%
to
$350.7 million
.
•
Net income per diluted share rose
15%
to
$0.78
from
$0.68
one year ago, and non-GAAP net income per diluted share
increased
15%
to
$1.24
.
•
Total HSA Assets grew
14%
to
$37.9 billion
.
•
Returned
$108.1 million
to shareholders through stock repurchases.
Draper, Utah – August 27, 2026
– HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the largest independent health savings account ("HSA") custodian by account volume and a leader in consumer-directed benefits ("CDBs"), today announced financial results for its second quarter ended July 31, 2026.
"HealthEquity delivered a record-setting second quarter, with record Adjusted EBITDA margin of 48%, record HSA accounts of 10.7 million and record HSA Assets of nearly $38 billion," said Scott Cutler, President and CEO of HealthEquity. "These results reflect strong execution across the business and the durability of our model as growth comes from more places, member relationships deepen and technology-enabled efficiency improves how we serve members and clients. This momentum gives us confidence to raise fiscal 2027 guidance and enter the second half focused on scaling efficiently and creating long-term value."
Second quarter financial results
Revenue for the second quarter ended July 31, 2026 was $350.7 million, an increase of 8% compared to $325.8 million for the second quarter ended July 31, 2025. Revenue this quarter included: service revenue of $124.4 million, custodial revenue of $175.9 million, and interchange revenue of $50.4 million.
Net income was $65.6 million, or $0.78 per diluted share, for the second quarter ended July 31, 2026, compared to $59.9 million, or $0.68 per diluted share, for the second quarter ended July 31, 2025. Net income margin was 19% for the second quarter ended July 31, 2026, compared to 18% for the second quarter ended July 31, 2025.
Non-GAAP net income was $103.8 million, or $1.24 per diluted share, for the second quarter ended July 31, 2026, compared to $94.6 million, or $1.08 per diluted share, for the second quarter ended July 31, 2025.
Adjusted EBITDA was $167.0 million for the second quarter ended July 31, 2026, an increase of 11% compared to the second quarter ended July 31, 2025. Adjusted EBITDA was 48% of revenue, compared to 46% for the second quarter ended July 31, 2025.
Account and asset metrics
New HSAs from sales were 202 thousand, an increase of 24% compared to the second quarter ended July 31, 2025. HSAs as of July 31, 2026 were 10.7 million, an increase of 8% year over year, including 0.9 million HSAs with investments, an increase of 20% year over year. Total Accounts as of July 31, 2026 were 17.8 million, including 7.0 million complementary CDBs.
Total HSA Assets as of July 31, 2026 were $37.9 billion, an increase of 14% year over year. Total HSA Assets included $17.4 billion of HSA cash and $20.6 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.9 billion as of July 31, 2026.
Stock repurchase program
The Company repurchased 1.2 million shares of its common stock for $108.1 million during the second quarter ended July 31, 2026. As of July 31, 2026, $948.4 million of common stock remained authorized for repurchase under the stock repurchase program.
1
Business outlook
For the fiscal year ending January 31, 2027, management is raising guidance and now expects revenues of $1.411 billion to $1.421 billion. Its outlook for net income is between $242 million and $248 million, resulting in net income of $2.88 to $2.96 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $392 million and $398 million, resulting in non-GAAP net income per diluted share of $4.66 to $4.73 (based on an estimated 84 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $628 million to $636 million.
See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.
Conference call
HealthEquity management will host a conference call at 8:30 a.m. (Eastern Time) on Thursday, August 27, 2026 to discuss the fiscal 2027 second quarter financial results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.
Non-GAAP financial information
To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.
•
Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
•
Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
•
Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.
Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP financial measures, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 17 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to save and improve lives by empowering healthcare consumers. For more information, visit www.healthequity.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future
2
efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:
•
our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;
•
our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
•
our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;
•
the impact of fraudulent account activity involving our member accounts or our third-party service providers on our reputation and financial results;
•
our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
•
the significant competition we face and may face in the future, including from those with greater resources than us;
•
our reliance on the availability and performance of our technology and communications systems;
•
potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
•
the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
•
our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
•
our reliance on partners and third-party vendors for distribution and important services;
•
our ability to develop and implement updated features for our technology platforms and communications systems; and
•
our reliance on our management team and key team members.
For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2026 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Relations Contact
Richard Putnam
801-727-1000
rputnam@healthequity.com
3
HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets
(in thousands, except par value)
July 31, 2026
January 31, 2026
(unaudited)
Assets
Current assets
Cash and cash equivalents
$
256,003
$
318,927
Accounts receivable, net of allowance for doubtful accounts of $1,067 and $924 as of July 31, 2026 and January 31, 2026, respectively
122,193
123,696
Prepaid expenses and other current assets
82,008
69,658
Total current assets
460,204
512,281
Property and equipment, net
4,823
3,177
Operating lease right-of-use assets
32,874
36,310
Intangible assets, net
1,047,797
1,097,172
Goodwill
1,648,145
1,648,145
Other assets
77,520
83,247
Total assets
$
3,271,363
$
3,380,332
Liabilities and stockholders’ equity
Current liabilities
Accounts payable
$
8,592
$
12,159
Accrued compensation
37,913
60,392
Accrued liabilities
97,300
74,388
Operating lease liabilities
9,970
9,911
Total current liabilities
153,775
156,850
Long-term liabilities
Long-term debt, net of issuance costs
931,062
957,379
Operating lease liabilities, non-current
29,984
34,190
Other long-term liabilities
73,999
31,007
Deferred tax liability
92,433
93,710
Total long-term liabilities
1,127,478
1,116,286
Total liabilities
1,281,253
1,273,136
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2026 and January 31, 2026, respectively
—
—
Common stock, $0.0001 par value, 900,000 shares authorized, 82,909 and 85,007 shares issued and outstanding as of July 31, 2026 and January 31, 2026, respectively
8
8
Additional paid-in capital
1,896,571
1,916,989
Accumulated earnings
162,583
195,906
Accumulated other comprehensive loss
(69,052)
(5,707)
Total stockholders’ equity
1,990,110
2,107,196
Total liabilities and stockholders’ equity
$
3,271,363
$
3,380,332
4
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations (unaudited)
Three months ended July 31,
Six months ended July 31,
(in thousands, except per share data)
2026
2025
2026
2025
Revenue
Service revenue
$
124,444
$
117,873
$
247,376
$
237,657
Custodial revenue
175,936
159,876
350,270
316,331
Interchange revenue
50,352
48,086
107,727
102,691
Total revenue
350,732
325,835
705,373
656,679
Cost of revenue
Service costs
73,170
75,156
151,496
163,161
Custodial costs
12,083
11,137
23,738
21,884
Interchange costs
7,525
6,947
15,873
14,728
Total cost of revenue
92,778
93,240
191,107
199,773
Gross profit
257,954
232,595
514,266
456,906
Operating expenses
Sales and marketing
23,215
19,922
50,048
45,906
Technology and development
73,923
64,804
141,690
126,240
General and administrative
34,869
29,990
66,000
55,526
Amortization of acquired intangible assets
26,286
27,001
52,801
54,003
Merger integration
971
1,266
2,084
2,541
Total operating expenses
159,264
142,983
312,623
284,216
Income from operations
98,690
89,612
201,643
172,690
Other expense
Interest expense
(12,605)
(14,955)
(25,193)
(29,813)
Other income, net
1,780
3,391
3,828
6,124
Total other expense
(10,825)
(11,564)
(21,365)
(23,689)
Income before income taxes
87,865
78,048
180,278
149,001
Income tax provision
22,221
18,194
45,216
35,232
Net income
$
65,644
$
59,854
$
135,062
$
113,769
Net income per share:
Basic
$
0.79
$
0.69
$
1.61
$
1.31
Diluted
$
0.78
$
0.68
$
1.60
$
1.29
Weighted-average number of shares used in computing net income per share:
Basic
83,374
86,550
83,885
86,601
Diluted
84,014
87,746
84,578
88,153
5
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of comprehensive income (unaudited)
Three months ended July 31,
Six months ended July 31,
(in thousands)
2026
2025
2026
2025
Net income
$
65,644
$
59,854
$
135,062
$
113,769
Other comprehensive income (loss)
Cash flow hedges
Net unrealized gains (losses)
(37,322)
203
(63,219)
203
Reclassification of net (gains) losses included in net income
22
—
(126)
—
Net change, net of income tax benefit (expense) of $12,135, $(70), $20,598, and $(70), respectively
(37,300)
203
(63,345)
203
Total other comprehensive income (loss)
(37,300)
203
(63,345)
203
Comprehensive income
$
28,344
$
60,057
$
71,717
$
113,972
6
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)
Six months ended July 31,
(in thousands)
2026
2025
Cash flows from operating activities:
Net income
$
135,062
$
113,769
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
80,169
77,195
Stock-based compensation
41,616
33,404
Amortization of debt discount and issuance costs
558
533
Amortization of gains on derivatives
(168)
—
Deferred taxes
19,321
30,711
Changes in operating assets and liabilities:
Accounts receivable, net
1,503
6,842
Prepaid expenses and other current and non-current assets
(12,581)
(20,650)
Operating lease right-of-use assets
3,436
3,339
Accrued compensation
(21,095)
(35,032)
Accounts payable, accrued liabilities, and other current liabilities
(13,595)
(3,785)
Operating lease liabilities, non-current
(4,206)
(3,951)
Other long-term liabilities
3,665
(1,771)
Net cash provided by operating activities
233,685
200,604
Cash flows from investing activities:
Capitalized software development costs
(30,720)
(26,464)
Purchases of property and equipment
(1,340)
(859)
Settlement of derivatives, net
(7,759)
—
Net cash used in investing activities
(39,819)
(27,323)
Cash flows from financing activities:
Repurchases of common stock
(231,054)
(125,810)
Principal payments on long-term debt
(26,875)
(50,000)
Settlement of client-held funds obligation, net
480
596
Proceeds from exercise of common stock options
659
10,446
Net cash used in financing activities
(256,790)
(164,768)
Increase (decrease) in cash and cash equivalents
(62,924)
8,513
Beginning cash and cash equivalents
318,927
295,948
Ending cash and cash equivalents
$
256,003
$
304,461
7
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)
Six months ended July 31,
(in thousands)
2026
2025
Supplemental cash flow data:
Interest expense paid in cash
$
23,350
$
28,362
Income tax payments, net
35,586
6,507
Supplemental disclosures of non-cash investing and financing activities:
Capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation
3,434
3,380
Purchases of property and equipment included in accounts payable or accrued liabilities
1,294
155
Repurchases of common stock included in accrued liabilities
3,255
1,246
Exercise of common stock options receivable
57
—
Stock-based compensation expense (unaudited)
Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows:
Three months ended July 31,
Six months ended July 31,
(in thousands)
2026
2025
2026
2025
Cost of revenue
$
2,713
$
3,114
$
5,500
$
6,501
Sales and marketing
3,229
1,529
7,753
6,399
Technology and development
6,178
5,732
10,131
11,652
General and administrative
10,090
8,693
18,232
8,852
Total stock-based compensation expense
$
22,210
$
19,068
$
41,616
$
33,404
Total Accounts (unaudited)
(in thousands, except percentages)
July 31, 2026
July 31, 2025
% Change
January 31, 2026
HSAs
10,739
9,989
8
%
10,570
New HSAs from sales - Quarter-to-date
202
163
24
%
553
New HSAs from sales - Year-to-date
374
312
20
%
1,040
New HSAs from acquisitions - Year-to-date
—
—
*
—
HSAs with investments
939
782
20
%
832
CDBs
7,016
7,153
(2)
%
7,221
Total Accounts
17,755
17,142
4
%
17,791
Average Total Accounts - Quarter-to-date
17,710
17,044
4
%
17,462
Average Total Accounts - Year-to-date
17,772
17,083
4
%
17,220
*
Not meaningful
HSA Assets (unaudited)
(in millions, except percentages)
July 31, 2026
July 31, 2025
% Change
January 31, 2026
HSA cash
$
17,369
$
17,035
2
%
$
17,982
HSA investments
20,552
16,102
28
%
18,482
Total HSA Assets
37,921
33,137
14
%
36,464
Average daily HSA cash - Quarter-to-date
17,388
17,017
2
%
17,090
Average daily HSA cash - Year-to-date
17,547
17,149
2
%
17,082
8
HSA cash maturity schedule
The following table summarizes the amount of HSA cash held by our depository partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of July 31, 2026:
Year ending January 31, (in billions, except percentages)
HSA cash expected to reprice
Average annualized yield
Remainder of 2027
$
2.3
1.5
%
2028
2.5
4.0
%
2029
1.8
3.8
%
2030
2.3
4.4
%
Thereafter
7.8
4.4
%
Total (1)
$
16.7
3.9
%
(1)
Excludes $0.7 billion of HSA cash held in floating-rate contracts as of July 31, 2026.
Client-held funds (unaudited)
(in millions, except percentages)
July 31, 2026
July 31, 2025
% Change
January 31, 2026
Client-held funds
$
931
$
818
14
%
$
1,090
Average daily Client-held funds - Quarter-to-date
936
884
6
%
879
Average daily Client-held funds - Year-to-date
986
893
10
%
864
Reconciliation of net income to Adjusted EBITDA (unaudited)
Three months ended July 31,
Six months ended July 31,
(in thousands)
2026
2025
2026
2025
Net income
$
65,644
$
59,854
$
135,062
$
113,769
Interest income
(1,760)
(3,364)
(3,647)
(6,097)
Interest expense
12,605
14,955
25,193
29,813
Income tax provision
22,221
18,194
45,216
35,232
Depreciation and amortization
15,669
11,453
27,368
23,192
Amortization of acquired intangible assets
26,286
27,001
52,801
54,003
Stock-based compensation expense
22,210
19,068
41,616
33,404
Merger integration expenses
971
1,266
2,084
2,541
Amortization of incremental costs to obtain a contract
2,139
1,951
4,255
3,877
Costs associated with unused office space
1,016
723
1,702
1,575
Other
(20)
(27)
(181)
(27)
Adjusted EBITDA
$
166,981
$
151,074
$
331,469
$
291,282
Net income and Adjusted EBITDA as a percentage of revenue (unaudited)
Three months ended July 31,
Six months ended July 31,
(in thousands, except percentages)
2026
2025
$ Change
% Change
2026
2025
$ Change
% Change
Net income
$
65,644
$
59,854
$
5,790
10
%
$
135,062
$
113,769
$
21,293
19
%
As a percentage of revenue
19
%
18
%
19
%
17
%
Adjusted EBITDA
$
166,981
$
151,074
$
15,907
11
%
$
331,469
$
291,282
$
40,187
14
%
As a percentage of revenue
48
%
46
%
47
%
44
%
9
Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)
Outlook for the year ending
(in millions)
January 31, 2027
Net income
$242 - 248
Interest income
(7)
Interest expense
50
Income tax provision
81 - 83
Depreciation and amortization
54
Amortization of acquired intangible assets
104
Stock-based compensation expense
87
Merger integration expenses
5
Amortization of incremental costs to obtain a contract
9
Costs associated with unused office space
3
Adjusted EBITDA
$628 - 636
Note: Values presented may not calculate due to rounding.
Reconciliation of net income to non-GAAP net income (unaudited)
Three months ended July 31,
Six months ended July 31,
(in thousands, except per share data)
2026
2025
2026
2025
Net income
$
65,644
$
59,854
$
135,062
$
113,769
Income tax provision
22,221
18,194
45,216
35,232
Income before income taxes - GAAP
87,865
78,048
180,278
149,001
Non-GAAP adjustments:
Amortization of acquired intangible assets
26,286
27,001
52,801
54,003
Stock-based compensation expense
22,210
19,068
41,616
33,404
Merger integration expenses
971
1,266
2,084
2,541
Costs associated with unused office space
1,016
723
1,702
1,575
Total adjustments to income before income taxes - GAAP
50,483
48,058
98,203
91,523
Income before income taxes - Non-GAAP
138,348
126,106
278,481
240,524
Income tax provision - Non-GAAP (1)
34,586
31,526
69,620
60,130
Non-GAAP net income
103,762
94,580
208,861
180,394
Diluted weighted-average shares
84,014
87,746
84,578
88,153
GAAP net income per diluted share
$
0.78
$
0.68
$
1.60
$
1.29
Non-GAAP net income per diluted share
$
1.24
$
1.08
$
2.47
$
2.05
(1)
The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.
10
Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)
Outlook for the year ending
(in millions, except per share data)
January 31, 2027
Net income
$242 - 248
Income tax provision
81 - 83
Income before income taxes - GAAP
323 - 331
Non-GAAP adjustments:
Amortization of acquired intangible assets
104
Stock-based compensation expense
87
Merger integration expenses
5
Costs associated with unused office space
3
Total adjustments to income before income taxes - GAAP
199
Income before income taxes - Non-GAAP
522 - 530
Income tax provision - Non-GAAP (1)
131 - 133
Non-GAAP net income
$392 - 398
Diluted weighted-average shares
84
GAAP net income per diluted share
$2.88 - 2.96
Non-GAAP net income per diluted share
$4.66 - 4.73
Note: Values presented may not calculate due to rounding.
(1)
The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.
11
Certain terms
Term
Definition
HSA
Health Savings Account, which is a financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis.
CDB
Consumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits.
HSA member
Consumers with HSAs that we serve.
Total HSA Assets
HSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments held by our custodial investment fund partner.
Client
Our employer clients.
Total Accounts
The sum of HSAs and CDBs on our platforms.
Client-held funds
Deposits held on behalf of our Clients to facilitate administration of our CDBs.
Network Partner
Our health plan partners, benefits administrators, and retirement plan recordkeepers.
Adjusted EBITDA
Earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
Non-GAAP net income
Calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
Non-GAAP net income per diluted share
Calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.
12
EX-101.SCH
3
hqy-20260827.xsd
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
0000001 - Document - Cover Page
link:presentationLink
link:calculationLink
link:definitionLink
EX-101.LAB
4
hqy-20260827_lab.xml
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line Two
Entity Address, Address Line Two
Entity File Number
Entity File Number
Cover page.
Cover [Abstract]
Title of 12(b) Security
Title of 12(b) Security
Local Phone Number
Local Phone Number
Document Period End Date
Document Period End Date
Soliciting Material
Soliciting Material
Entity Address, Address Line One
Entity Address, Address Line One
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Entity Registrant Name
Entity Registrant Name
Amendment Flag
Amendment Flag
Pre-commencement Issuer Tender Offer
Pre-commencement Issuer Tender Offer
Entity Address, State or Province
Entity Address, State or Province
Entity Address, City or Town
Entity Address, City or Town
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Written Communications
Written Communications
Security Exchange Name
Security Exchange Name
Trading Symbol
Trading Symbol
Document Type
Document Type
City Area Code
City Area Code
Pre-commencement Tender Offer
Pre-commencement Tender Offer
Entity Central Index Key
Entity Central Index Key
Entity Emerging Growth Company
Entity Emerging Growth Company
EX-101.PRE
5
hqy-20260827_pre.xml
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
XML
7
R1.htm
IDEA: XBRL DOCUMENT
Cover Page
Aug. 27, 2026
Cover [Abstract]
Document Type
8-K
Document Period End Date
Aug. 27, 2026
Entity File Number
001-36568
Entity Registrant Name
HEALTHEQUITY, INC.
Entity Incorporation, State or Country Code
DE
Entity Tax Identification Number
52-2383166
Entity Address, Address Line One
15 West Scenic Pointe Drive
Entity Address, Address Line Two
Suite 100
Entity Address, City or Town
Draper
Entity Address, State or Province
UT
Entity Address, Postal Zip Code
84020
City Area Code
801
Local Phone Number
727-1000
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common stock, par value $0.0001 per share
Trading Symbol
HQY
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
Entity Central Index Key
0001428336
Amendment Flag
false
XML
8
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
.report table.authRefData a {
display: block;
font-weight: bold;
}
.report table.authRefData p {
margin-top: 0px;
}
.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
.report table.authRefData .hide a:hover {
background-color: #2F4497;
}
.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
.report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
.report hr {
border: 1px solid #acf;
}
/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
.report td.pl div.a {
width: 200px;
}
.report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}
.report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}
.report .rou td {
border-bottom: 1px solid black;
}
.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}
/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
.report .nump {
padding-left: 2em;
}
.report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}
.report .text .big {
margin-bottom: 1em;
width: 17em;
}
.report .text .more {
display: none;
}
.report .text .note {
font-style: italic;
font-weight: bold;
}
.report .text .small {
width: 10em;
}
.report sup {
font-style: italic;
}
.report .outerFootnotes {
font-size: 1em;
}
XML
9
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
11
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.26.1
html
1
23
1
false
0
0
false
0
false
false
R1.htm
0000001 - Document - Cover Page
Sheet
http://healthequity.com/role/CoverPage
Cover Page
Cover
1
false
false
All Reports
Book
All Reports
hqy-20260827.htm
hqy-20260827.xsd
hqy-20260827_lab.xml
hqy-20260827_pre.xml
http://xbrl.sec.gov/dei/2026
true
false
JSON
13
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"hqy-20260827.htm": {
"nsprefix": "hqy",
"nsuri": "http://healthequity.com/20260827",
"dts": {
"inline": {
"local": [
"hqy-20260827.htm"
]
},
"schema": {
"local": [
"hqy-20260827.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.sec.gov/dei/2026/dei-2026.xsd"
]
},
"labelLink": {
"local": [
"hqy-20260827_lab.xml"
]
},
"presentationLink": {
"local": [
"hqy-20260827_pre.xml"
]
}
},
"keyStandard": 23,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 2,
"http://xbrl.sec.gov/dei/2026": 2
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 24,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2026": 23
},
"report": {
"R1": {
"role": "http://healthequity.com/role/CoverPage",
"longName": "0000001 - Document - Cover Page",
"shortName": "Cover Page",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "c-1",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "hqy-20260827.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c-1",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "hqy-20260827.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AmendmentFlag",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amendment Flag",
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CityAreaCode",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "City Area Code",
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"terseLabel": "Cover page.",
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Document Period End Date",
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentType",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Document Type",
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, Address Line One",
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine2": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine2",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, Address Line Two",
"label": "Entity Address, Address Line Two",
"documentation": "Address Line 2 such as Street or Suite number"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, City or Town",
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, Postal Zip Code",
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, State or Province",
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Central Index Key",
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Emerging Growth Company",
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityFileNumber",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity File Number",
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Incorporation, State or Country Code",
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityRegistrantName",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Registrant Name",
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Tax Identification Number",
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "LocalPhoneNumber",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Local Phone Number",
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Pre-commencement Issuer Tender Offer",
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Pre-commencement Tender Offer",
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "Security12bTitle",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Title of 12(b) Security",
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SecurityExchangeName",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Security Exchange Name",
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SolicitingMaterial",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Soliciting Material",
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "TradingSymbol",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Trading Symbol",
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "WrittenCommunications",
"presentation": [
"http://healthequity.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Written Communications",
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r6"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
}
}
}
ZIP
14
0001428336-26-000040-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001428336-26-000040-xbrl.zip
M4$L#!!0 ( %E@&UU[-/4N) \ +5@ 0 :'%Y+3(P,C8P.#(W+FAT
M;>T<:W?:./9[?X66[DZ3<[#Q@W<2]C"$MDS;)!/2[
Z]L$PB/0$H(Z4P_I-B2KG3?#TD^_?=XX)%;)D(>^&=O3-UX0YCO!"[W>V=O
MZNU&J_7FW[57I__0M-]^OOY(S@,G&C!?DH9@5#*7C+CL$]EGY$L@OO);2JX\
M*KN!&&A:/*P1#">"]_J26(953+NEK:)JF-0P.B;32@7J:*6B6=#*5K&K6<4.
M-:A-2Z;M9GM55BJZ'=8M:A;M=K5\IV)HG:)K:95\I>QTBHY1=/-9M]IU2B5:
MR1MVH5S,%VD!8+@ERS;RME,V7--5\_8EX QX^^%9IB_EL)K+C48C?63K@>CE
MS$JEDAMCGTS
<)OCOL=]AK3)24']$%&G$HB9LPQ Q2AK
MMGD'9P[$N",\-2/TM&< S4R[O/^Z.2U#,RS-M%(@XY O0](R##/WVZ>/;:?/
M!E3C?BBI[[!TE,ON1JEI4W2A 2
N]NK5JU/)I<=J_6\3#3$URE;I-!>_.\W%D#N!.ZF=NOR6
MA'+BL;.,R\.A1R=5/_ 9S,_'5>S(1/R3NR[SU4]HOP#]$=R)IQ_+:]8]RS@:
MR(A/!PB)\6K3A^DF#5B
Y.:A;
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MO
)CYO. P>>+UDWSG+1OZC?-
M]OSR9Q;^O&ML-QN?KULWK6:;U"_.2?.WQOOZQ;LF:5Q^^M1JMUN7%WM?N+'1
MPK_0L ]1A S\+#G7&SKX_T*^LO5BE\G6P3#G+7A>LKG-3:.GV '%)A
75Y?7.8:[R*1!A1B&QE0-K,P7"*F#8)
M!#$+1^XQ";J'N>X;B+UAO9'@DH,W;HZ=/CAC1NJ.A#43LV+G?RA90L^(B%VS
M82 D.4J?&07?R$))V"WF)T(U,_?X1T%>V9OM3
*,- $0?AVDNG6@3H*+&_&DXF*G5HUX$1+5*696_?9^=DK3CL;1#)Q 0JFA
M+X\.0U9-?YRDP72
A'PL#C
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M8,!#W"\E:$U)K*5_4W
*GI8*3W*F5H[XH _B."/C7T#?EZ*FV TS18JD"T(
M.D2[,8]X=HM=FKDY5+QP*:X@,>'J',.&>8MI9&J?)>TO
LE\+GH\V11][6!:-SZ%J KF'>1_9X"YI^#,!+7O4#_UX69-J9
M6LDJ =MVH33/LX5PGP?YY3Q(!"I+0)Z]"!TF ;$B2.@LH;Y+;IC'ADBBQ%_-
M]D26)%W5'DQ:?OSI==DR2R
MN+7?NJI=T0V[L&U=M5+6*\;RIL=OO6Q=$=\X0%RWB;%9@#A#TAFX!87-/D37
M+N.1@3YSOJJ#I70(WG4( "&DZ01CTF%>,$+1Q49U *.L?2!=[J%]XB'!V,]W
M0:1E %(]B#Q)?19$H3
B1B8#@@Z0*
Q.R!!'
M=183,IPY"G(=@8'*6X5$%N3\:0L\9'%DEDCC[36Q;$.'CJOMYLME>!MLDP,8
M^[U/H(5(]DVY73@@;M]A008)&HNL-O,4XLP9;L\=J)GR.@^F7_7\$=E])1CJ
M-AZ]5:?5T)P*".(P7-Z,[<4#8CM@HSDSZ#RH[6;>U:RCSO%F0A#W_0N(02L,
M(R8>(0RE%RT,-M/R1\YFPI#T712&_6"H*FLSWBF.9)B 6&BX['2C$O(DL@%<
MIJ'*BSCM4- KE?5[^!N?K
%_[U5N&_P8DQ\_M+I
M$P<2R'"+7>,7@Z6@JOS1G@PZ@7
)-I?ZZ\RZK9>XO2NY$/6/MG-*ZDJF]__7WOZFXK="F\4U\I/1^
MC(>687ZKPS+B6P@7]?9Y_5?RS@L@!H0HPX,X@WRBXBN3:YFP46GK((I2+=_%
M2)&1SH0XJD %:_D*!I*IPR3WJD<\)+ N"#-QN3W2$\%(]C'@'&)%B8;$95V8
MPB7<3\H,1B$-Q^[5&.*+'/8TVOSIM5DLG:B*@U$XQM(N L"WQ@G8',V*?RX"
M6W8])(4:CTE 8SB+@([U^/6C\YM9G5 ;\_MD6',%\1^3=Y#/D"8$+B.?VGM*
MP.(-P!2'=PJ%1HS!AKF79:[,O?:>>JW>1IL7H
O4N%&\:E:7=5TF
]>0AT%,MZI@'L4]QH6+R7>^7 F5<3>$=L"A1W)QR$-WF>._?7$7X/>8UA&,
M?M5H%WQ]E7HC.@DQR7NR2]1/H1@/'V>--4.R ;%TP[KS$_-_KUD8>3)$X;H$
M>4XJ*KBC_'8JL(T % @;-C0&Q7EC4'PRG)<74RY]
:W"&QS
MEK1\1P=/'T:@;Q14CX58=_$8!66G4D(NA0WH>/N\PR6I5'03]5'V(3P MRSN
M+BMBKI7N9^DO@SX8]G%_^OT1C&3F$ 4<.PRM4S<2/@_[\:[
RR2_"L@06X<(^YZK=YH@PGF#M0
Q83["
#?,OWV!9(474"R7;ER%RJ)$&?14*N\;^:SF-HS2%?0
M/XV5O.+&*)-(0G W,'
69Q?1!@YX(R2=1R<>"X_9:A,5D4WS%4FZ\XP
MJ7->6!%.Y5%)<7AH>"Y70[R?_N"*G__\!7@\+'%L6^HU+=TRMKM#M@I4N: 7
M'J@:/_G-KWU=0(E7XS(GN0]05;8#>T%>E!CIBT#?827SL'$^9Z$C^' N^'CB
M>S)/A_SR6@_ZW+WP<]V65K>[2[S,PEJFGM)T!7.?%V*Q?)\\T[+(],-6C$+<
MX_?")"34NA.K],W2^W*@]B)G@L4DA@3_NR3 =%5
0B./_/ 3VD6\1%6#T21SA_!*!U[?-&!#8 +KG&V3[U@S3R#^[8NP6+1,/
M,C8"6 6Y@D04Y 2X"[*/!V[/J:3QY:2C.#:7<96QI1PXP2\';GX)9:.C@W_G
MY\O"0N3B;HY>/ME55FNC0+K=>G=1O_E\W?S>8RX'<0)UPZAZ]HM0<74/3+)(
MDH1-L\HE94$7;:]#(RSEJ3) DO[#-) 0AL!B:,!D6F+V#+EB%[T" E(>)ND
MR2>+?!BCP-%(]@,!R+F+J=D+"?,+>=TL[N8##R7=*)=V]M&)]6>_-SX:DM=+
MUD;'R!]U<70WG\[9]^<+EGVF9C^A^2XW8C>,0? +7-7[0=P31R7/@.;/D^H6
M2.WC%O3^<,^%.?(+'8 W^!@YU.?T,>+\8Y$$3Q'L4"!V
?::_]'U!+ P04 " !98!M=+I9
2TR,#(V
M,#@R-RYX
,GSXM%^B69UT#3*$; 41!CM9454A5@'YP\4Q?"+JOB2JX:#">
M6]H-;[>"EI5"<1@G#N:\8AI&) S3"/#HDF1XE$27>!PG!8Z3E(1D2$;1,/]8
M3F&4Y"D4"8Y)4>"+=!+B-,EC/+F8C+,TR<(DO[!!-W(JLPH:@G1K3$XW
!<:=$@H-7J^UO
M= 6DUC*L.JJV?L:;P'0;CN.1AXA2@J:=@CLMRRT4I*O5S.O8JB,U+2CD6O,:
MC*H'@%=N140)ZBMI0+8D@[](.A\@9*2@3
MP=95(1ENGN=OHM>$:4
M'8N3%/.''0\;$XYB/(S\C
R/R\^GM]QFW!-<5!
!6\);T)U$O)O;&[/
M;V^X)_>0=X@9J;.N/I^W+^LDK3
FUU@&.M;8C'-H)MI%\5FVJ!),8-=+ J*I!QA9"F@E2;Y
M]TO*=B)9E$U2MK(WB6(?G_>\QWXLBJ3R\R^/RP+\8'R55^6[F7OFS K247S
M
?/S7R#\XQ]?+\&O%;E?LK(&%YSAFE'PD->WH+YEX/>*
M_YG_P."JP'56\26$Y\W++JJ[)YXO;FO@.5ZT#=L^R]\Z+G:
2&
M,/&B#'I1BAWLX]CUZ4^+MRR.:,JR"'HXRV"0(@>F$?4@"E!"TH@X$0V:I$5>
M_OE6_DCQB@%AKUPU?[Z;W=;UW=OY_.'AX>PQY<59Q1=SSW'\^39ZM@E_[,4_
M^$VTBQ":-\\^AZYR5:!(Z\[_^.WRFMRR)89YN:IQ2:3 *G^[:AZ\K BNFZX?
MK L,1LB_X#8,RH>@ZT'?/7M
!5P;ZR#,C?W[Y^&I1$
5?A\3F(\H_4KUUO]8C%-?8_7RL&O?U]//1RKT1WQ#L] 6W9$:7O/Y ?2CI
M5)_=9ZG1I9^^XF-]+*H:%Q-\+%YD6B47\H%+<;21D8GV?)DV.INO[E:I[+%F
M)67K;\M.:I#3=S-Q])VR_/N'LL[KIQO\^(F*LU^>Y>LO[\_WRY3Q[[OGL#"#
MB(8A="+"HI"&:12C[_7SA_L[*^&WZVT=C9BFTLS :SW +&>KZIZ3]=E.J,LS
M_;J@\[4V$.*@JP[6\C_/7RH>TZ]BNBX4TS2@(AV)0I[<*[YKKB+ZYEZH60EW
MC;,5(V>+ZL=
5PYGGO/7O/MW5C3@ZT
3UD/3'LQ(X'
M8P?A.',HI@2;(:M0F0;7C>)/VP,@M<'-0V6*JZI/NJB.=&^%J;EQ"TSW&!N!
MJ"KKQ'CN,=9'
Y*#6C\27Y-!!*/
8!59]!R-H:B6;&**^C3X[BAAS9"ZJ'XR_3U
&I=$"=WC!SO0IZ5H_C(BU(3,^UE[^LQ7Z
M[W'H4!9OA48WTV1<* VTH5 'F!-QS<@]%WBY7GJ3UP7;A8*((\3"% 9!FC'7
MH0Z.,ETH=I.?F(M& U09<+V_I7\'6W5]1GK-.(S)&(MFI)BZ,P)FR(85,[UD
MDV$S9*--SF",.3QR]KFXNJW*@1&8SR*(_32&A-"$)%[J93'3A6
1
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M($Z]$$9>AE!$B>
X89F)P5QK R$.I+HEE]U&&8)I;7\
( ^UI$97
M-$"^: (I:LKA3D]T";1W:L6>KDD+Y-1.1L"VDW!BS-1V^H -Q)FC]5Y<(%)Y
MD?BQP(O^;BD$D00K(REU:> X(=4^U74RGQBF9RT@Q?0AZKH_3(^U)S-L-.T8
MX:(LW8J3;J;) %$::).A#C!'XHJSBVHI$A$FLWU:K>X9OY%;$?F7+%-,R$
S7KD-B)P1'RD+3TP;H L*X -"7HXW2P
OK^[:_V!LR-O][;
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MVC1"
'^1KKU PO0Y-66Z953D9MF^XDG'SKM,J.
M:ONT,LX
3H,M7)?&*8-EI@
M+:8/4=?]87JL/9EAHVG'"!=EZ5:<=#--!HC20)L,=8#]%ND;\=(>$22 J9\A
MB-((N21*,R_U37=&R\0G!N)YG[#4,M\%W5@_C(.M(3,:]+Q8;71N%SYJ?W.3
M:/)MS>WR5;N9.\];W*TIITDXPZKY"Y=F,"5) $.6T10[ 4L=[3TD[<0G!J&9
M/I-:AG,1'>^'2;!U9$:"IAFS6S45E=O=J=E.--V-FHKR._=IJIX?O="]9XF;
MQH$8,WD(XB@( Y2E?HBUKT.&9:9>W#[*JO:H]>S76
XM9HOUS=J,3D^8&;$=/ANQHDGP <,]:>\AP)M,?NP9'PA
M+K'^R:N'^E; ?(?+I]W=Q?(_>&!""4PP25P4^HE#J1EL2IUID-M*@[4VV(B;
M@J?NE"Y^H_U;06AJW0+%O<9& *G..S&6>\WUX=P?/H1H^]VX%$?G;[:/Y.O_
MGWO^YG]02P,$% @ 66 ;7?770;('!@ S, !0 !H<7DM,C R-C X
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M9K3/.1\WWWX96J:[!MK+^N./;RZNU0SF J5Y68E
A^A#R"0K\PV6I1R<'GO<@ARDRN(+$JU_?7YU_,3D#D=G8_7N;
M5JM#5
K5:P/&H3.>+[,NQF8'$7N??%:K#BAF):YN_
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MD&389[YFD=!R #"^ZT0G3B+7.1E.9R>PN1'+
.+O6T#?WL2G"5(4.$CG\4,
M6VU\S-4 @.PPW0F.V'4X^FKJ*!BD17<@[
MTMJW^2[@&"G.9:@2S0D>,%]\-=P)"OZ+0/%,/5U"
MHBF9WIE+4]REN6I73-CFO(B&B(>2X$!1>_\U8+K8LMZMCX5_$3KZ2.L2(I=%
M68GLGW2QJZ1.M+:Y+TGL1Z5$H**8\7@X0#9L=\/#X3[G0++N&8XZZYT:$+O\
MKE.>5%*BD,8$HC#FFOF]\WA'++F=%_D1GCFH?R82
M%0"D4!'#'/J%?=MBM] [W-SL)>&>P__!I%4%^:28SV_SQYOGLG5[%"LD_$36
M$&-?AQ %R?:>Y,\QL--L-Q <[F_V%W//-%P76:K2*LVG;VR!8U*1M:I?%B.1
M1!CYG$JJ$QI(S7NAT+;9C0.'^Y<]9=PS!)<&:H+!%K;-SFV]Z6_>)
" NK6+HHKG\B;M,K:CX P0(QKCA31H09&[6+8
M;^=\VV(W'!SN5?:2<,_AOS&B?JCQ>C6716L-C.+0ICG!4* IE3HA0@3]GO?:
M,-
B@'(V#+;C0F'
M6Y#]Q=PS#:>VWM5US?LZ$]-6$S4*D%1 ;,)3"0XQ<$*#7A1LF.L6?8>[D,\7
M;["HOQBWQ+NP!TX.'K^H_]3_,W%R\!]02P,$% @ 66 ;7
V]:W/CQI(H
M^'U_!=:O:6\4>? F*'D<(7=[CGUVQO:X>^_$_;11!(HD3H, C8?4.K_^9A8
MOD2*!$@!!: <8;6$1Z$J,RLKW_G#,ET%/_ZP9-3[\?_ZX?\>C90/D9NM6)@J
M;LQHRCPE2_QPH?R/QY+/RFA4//4^6C_'_F*9*KJJV\K_1/%G_Y'F]U,_#=B/
MY3@__"W_^X>_\8_\,(N\YQ]_\/Q'Q??^_2O?<:D]G7J6.I^[IN;JCCXW'692
MPS.F'M.L_U_["EZ%Q_-WDO0Y8/_^U
_YF.\&&F4,'?$OJ0Q==.[)%NM:/Q\G\*%$0W\17CGPA)8
M_%4^8/F2&P51?/>URO^[QSNC.5WYP?/=OSW$/@W^C20T3&#HV)_GMQ/_7^Q.
MTV&J_,^G?.X3>#OP0U:N1=,L6, OC ;I\N>_,C]]5OYDZRA.$^4C
#/)@C397_\N#&F\ ##.
MHC2-5G<&3.W4LH_ \>0X-HQ37$FC-?YY(]BIYV"G(_)_@=\#_#M1HKF2+IF2
MY(#[JP"<'[I!YK'OOK:<^Y-+6E// Z(?!6P. SLE:'P >IC>C?#*&ZW*/+JJ
M[[YV=-W>S+>I#]_OP\$<6[CNWUB*4(Q6#/\!)I$ );[EU(YC6E._;1H>7_VH
MI%$+2_W&ML9VOL]AS,"/PN973A0*NRC
2WY9AU\^>/_,$A2D?O[IUT\?'MIEFMIPF*9F3\:J$%SSD +$
M8)UF*]RD)=9IVI)U=H]U_LD>69BU*V>VLDO:X9B&I8XG+7-,N5-J[90=I6P-
M6J[G!QD>.,F2QDR)HX2U(6Q8P]DZL'&
5&(>/'J4(74:&01N'H
M[P\/?^QJIB\V0,69?O)7+%%^8T_*G]&*AC#GFM-M'D*MZA8#VN[:6#?EV=B1
ML_%3E-) ^>7C@_*0)"Q-E$4,>[N%#6(.9X,8D_$TER1G4I+LU&[YDZ59'+9R
M@GRCJ
PNX8Q-7A)8Y]QE
M'V(*TA)1_K^4+A4D0TV[5QZR19:D.1KT2>Y7; $/Y71VW:%$^35TQ\J[WQX^
M?GCX;^[$4W[Y[__]O?+NNZ\-\W[W47Y!B6+N!.1_O(]6:QKF-[XG_'H H&<)
M2HX>6S.^_Y4E'T1)Z"/LC42AKAME<+GXPL>'_'W%!1A%GD]#9?:\>>@Q"C*0
M0%$RI4K J,<]CHH;A0E
>'S,7Y=(9"]G
&[!ZY-=L(G?)H1MD2+I[C@ 085CP7^(XL9 A/@%L4>
MC)VF&(ZPOW2B//F LOR94^;6:*Z8SK>D? KE@0)MW%>L@0JG%%R'(W#GN4)N
M@*="T#Z"9^4;PU&*@XWDA)90WU,^N@!)Y7V6!CBG/P!?/B
0 T C"/(U@H^\+<+.5S
\+*8
MPGP0:/"-*(N550304R@*.]$3P 8UHR37%U=1#$I20%V6$&7%5C.@G9@%%+^2
M+/UU H#'W9"/SMQE"'A?/(]82&
8>!E]*0\H;,]
M?F3%F/GLW ">3).Q\FGI)_!I# G)5LK"Q[>R!+?&'('D,F2\,?4!%',_<8'<
M@78GRB+S/8IW<3 >E+#KU5_28 [; ?8BS M@A.\A>9133(/G?!88RX(W H#I
M" 99*8\TR-B8(T"T_7&<5W_
+N :"!S8WIKVTXI"J-$/V*<&:OH!Q_C'[!A\#*OGM16P$KE&;?GO=O#6G
MZ@!65ZCAB.V.DX6F&@=[-D<56EUN3Q=3\R@1:F/U)G31#5P
WN;YWCLL!#H6]P10.%4Y"YTMAW.R($
MH&T=Y.I"'DUH ++@$PCZB((<'^DRRN +W@L"TLTK"(A_DW)!_IB(@3/0+I$P
MN \"Y-Z8_T8*60#E2_7@C,D_R;43/P21-T7Y-WFY*O5P4!"8N=GRH511SDQ[
M\H)C;B?U8A
D 33TO?A3%@
MWAY;1PEJ^/PVC#!C7-,I=+O\W03)?TY=5/MH"@J2M_)#']1&KLAMG@7DYL(D
MWVOY-T!36["0Q?C:"XF4%+!3#T!W$M;"T
G ?J> ZKJ(Z4JTV9^@?.!S
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M1<:FII5V5JZKP15]
3>CA>T4!",03_P5
MGZ>S9>#E"#EA,&]$05("G&Y.FBQ-4LJ)X/NQ\E];?)
,N*EV]WQ@RMC99/P1J6'%)C#^DW>?XY43B,7B0\_:D%-,.870B
MM@G.7>Z7"%'JV\AY2$[ARSFL0,;-8FYF1UTI=V,"MG([)AQ$7 8N=*A5E*2%
M8H56?N746/Z.-,S5FIP=E,^E^#*(Y2F_#JPAG]_V>\)A]SA[?A^%
'J;H;0]G]@./WV"_:(L$6^4NU%VYHL(<+AEVE 5.@9YZ=W/%.@K#A6,
M;OL>]_NG918G'GTF1QV^2!<>
%=0\D(5I(\
9BM'ZQG?9G_$C]@.\*
MY%9+5FART8[;#&&RJW;!<""],<3#,DW7'!7??6U.\A]^/,Z]S"R?#^R[CNR+
MUUF=:&LX9410DFQ=&$ XMHXN!G0-EJ#DG)^..4>$T])'59WQS1%@8/4KG'?7
M"'/ X
'BF-;Z]+(?]F/8,OSIU6R]1 $A-^2A(#,V1]
<$W(C+@S%%=Y1+I/A
M:
BPCQ
.\>,D(<.E<;X?4$1UR MIV[XH%:$Y37X(7\
M+ &>!9I_ZO,W#R;);63<0ACD(^&!$,U2&"T_;KBV28I[,/T( 5 *!5F8>^31
M#0^"XIJZ!6V[+.9#1,#[
(=X+J*U+OSEA?D&3AJ\O\$)D#
M$YBE^5-)-N.; P%"M]P
8*0R0*X)X&XZ;@%O!]IY$VZS<"\WMA9>Z
M\HO= ?#W^?XX=D#S^Q
V<\]$<4P014R0"M%CRZT?=8OK
,6@G5T9?E]3RG>DQU)7GV;X<" O9T;KRN)Q<_D>M
M=D%C3A3ER;8=&Y_<1.JEH(YX2:$PH DH5[L+D_Z_)3OOH7+E;V2)$H:H6.1'
M)4 FU[!*?X!+LUP)V
G?619!FT4< ^E2&D0T>(BDMG++X'C#RZ7V!
M,)AS *HB/@\@@D^& )3/L$M2H'MDE#!)7%3AFU6 Q\8(KG+Z18!F$<"*7\A%
M@)C7-T*(<&1Z.=/>6!9V5\^?Y^.'P+S'RJ];8N/.,SQ0+CYT
E>;S&>5Q6*4#K7@O7:(N\/KWD+3+KP&-+F$$=#H^<:H[3Z-<[2CIE)ZP
M U%0;'R7*ZNGA]HW^J 6@W&2VS>/OX40+^D+40SZ-2A/L"^\?*\_^NRI %'.
M,T_MM3)JM;HE*Y^W'^
IG[5;(0SP&^S/(F1!^IS!5<;/
+3M\+!DX%NAHNU'8&S#M %SR*)@XV&<
KG:@T&0(?E;@*"?EI&I8T
O,C48)\D[X
?RWY7254UPA5[F
1^L)1IH=7$X8^_SB(O57+Z^%
M*
N?*'6BYEKRG.4P0Q0M0,%B.>NO9PL]Q[F(B/0!3=IQ"CWCI6/
M17C)D9=P:?!H;@K-UCSJ$LA_71R''DTI0N"?F;?(9\D5_=VOH#VJ^ [(#1ER
MJP,H<]Y3@)E_$!5XAF %\@8" 84J5] !CWN3\S+^$:H\HJB?YQI^#J.GW%"1
MA?GOL9\ .U$P>95;1+A0L\,#X2",4#K>(,Q/2^48CM7<,;R[D= 3NP$6'SP/
M9\W'X1SQN8Q)X'X,E%/P4[AD_GBICQ9:[\9<_7H1X)?UD7>VG2%MK*_;6)%X
MRI14I!D/U!Q M 6SSS-+7X@(2\RV'X%RR@#D4NW0!EL!FI[E@
#'NIM$@
%G ?19D>AKL0\>:'Y<[C&GR>
M\[^M?A#SRR"3@B2$?/-YD\^\-9"A@3;+P_33;:3#B]@OB>_&V&V2\4BZ>882
M6RDND=('L4D@7\1Y=E#N*0%,H<,%9" _4C:E;) $=BTI*=9%D
3FA5NXN6_GX2*#<>MG*0W)A8,R-U7$H!@7H>42M8TJL"!+\5.TQ#B7
M
%S\L=
MW/SA7-J&"J/_5NUYA-V(X2T\2POM$/XLV^@ZH&J!Y(RR6J$=29PUMS4]]LB"
M:%TBHDC>R-9>'H+%:,Y#YZ4NNSVFU\!'4>I*S@E8>%\BLY$-F,<1;&(J4T97
M'#N?V7/^1U%"L#M.,85N \RV_MJMXV(GTL%//F^]%^L\_H1GKY4.BMQKL1NO
MEB
2-POW,4;:20OD8G9GSQ
,H>'LS
-;>HWA#!K!] *Z3MA=^
S[?^2'_''_I?E]N 2S
<\VQZ9AG[RMCK63]UX;5K/&CCFM->SK]PS;?)/)6I=-Z&\
Z>/;3A$%;RKH>2+O^TR(A2*#Q&>X_HV
MF]$Y1^N
8)%'X[H,I@H:<%X4^_O-1BS@]2:@X-WCVX<%5C!32@'V
M)@M7<:5?#01ZN1IP'(#G=A-U/R_B""3X43%'UV5L/K^_#8CKCRX<[%](&/DN
MSD(L70*GU$4;5E1H[XU>F63F_+^K^"_,K
,;[WWI&:B/R8-%7[/#WFR,F^_%R7ABB8?,LFXO+^"+2BW(0&BB.<1KQ66K
M8@B QQ?]S8T6IPIX+.J63535R"V35ZYS2[L55GI+=BR)KAM$9V@.F>J3EHFN
MO;-WQ\BTY_^Q.
ODQ
1_
S;J,?S^PR!VR!KTR
VJWC*5AR)=_8.DCWSN6\NY>ID>\1GV5Q !!J,_1
M03YS^B&?]19)]I385MM(NKT\,Q6./^2]9F[ "LX9W(Y8.,4F0=-6B:Z:]4ZI
M*F#HE*#1'_Q:FDYT1Q,9OT,14; 229&B@A:P=1[)#EK3-4))?RC5)(Y>TZ D
M%A^ZH333'^P:1)O4M-P(RH7.B4$3X5C0[YM22$4X+-X;1?,1%L:\7BCJ%CWJ
MQ)G4%'NZ+-ET"TDV,3156E : /6O+^O%7RF9=(K2-**:$S*9MNU
MD9DD-?>?F@U')89158?LME-,O!R-_]R6X,JS5+$_X3(*/%Y/V-&UR7W13?":
M/(Z+T-5VDD?U20XH V2G5)M, ^FT(KD)&U[39XP9EMD?W0S$=X@U;=L"*W,_
M!D5RFDXT:]HW35]4+AUG!SVB!^,!,"9DJLG4"K&19(/Z5OD DK;_:YC!)4)X
MWZS+TPDQ5.D"$!M)$Y,83N]R*,0/'KR6(73QW)F2Z:3M<#0I&YS%D58SW4%<
MT4!8CZ!;P49W3;Q[MVA0LPPRF50-3JD*@T[)%+W!K$T
-@_<,(33L81].WVF.C$-Z
C"<-U%S&LV41WJI8D;13#PTFF
MNY$#O4_TJ3OPOS6$++/!8AB45,VH61194 YT5AH2C@'QWK5IWB,U;]?,NZ"R
MT*WK2KOTP)5-<]X4L1]OFT(W2 ?IQ5@5IQW#'W%IZN YE$3YAO>RU+;=!HD"
M3Q*XIB1+BBW<:98NHQ@^X:$#I;R*#E<8A5=/S](DA5_0Z=)B?X8NVOCXSM/O
MI2568DG@@!UQV!>*(U'X"N^:GN9=CDZFZI0S(L="T[JXK*R+]LFJUB!I/QX6
M?@:@+#W 3#$%D@8*]I@9^:'BTK6?TGIE$;MX5&K$F=K$FE2-JY
?H;CX:U1T.X:
M=V"WR!!DU:E*M+K!3P)E23;AZNT6;G6BJ1.BU6U^*V*>Y'X03#Y8%2^TL$PJ
MJ%V%\UI874OL'2VZ=G.PB%BNK6[%Z%O#J#$Q\E+&4+7^H-Q$0]Y$]0I5B[.)
M^#'[MQ1KO98NLQVWXXK&"S_,)[!U.?[XPPQ?VG6S[;Q3 ,@R 8+K*.&6^;N8
M@?(-FO;]D^^ERP)ZNV\5,%"WK] 9K#=+3[\".'-'L-B8NNE=DJU@LL^[JW=9
MF++X-N2@J>?H0><=4@^
?#,QOMG&^=+17S
M#0N3#N@Z87?E+_>>GZP#^GSGAWP2_*7[ C,%Z6-ZUJ&XB<2
D0@*
MV;CX
5L=:R?OO3:LIH]5PZHU[.OW#-N4D^W49,W+
M)G1.LSM[Z)W4WZ<5!CEGM6Y
@N'3,F9,6<%SRT1AP*T\'AJC&!JY)&!4
MPG(W]M;_<@$DSY#G-5Z/YI?\S@^5=!EE,(27$(5]<1E,%0ZT/ A+@?..OC T
M7[%J03"-46$55G5!R'/W & -'0"2 JKPM5O:>H6T8/S)'EF8O>AH
7H]\^&..".M7-[\6/+'[T7:;$Q_?D;;SY8BRUWRU?3&*:58N<"1I.(HFN
M(T2G38@SJ>FVDD0GB:Y6O(2)I41KUN601">)KA;1&1-B6_TK12
1S # Q+-HD0&TFF0]2Z!1
AM
M:T(22^>PI!-[VG8)@MMGKQDB'JQY;L@-E-7^%*]$Z7M2.19;%B?M#'YUBSA&
MU::-$K]=P>]$M8A1V;,C\=L5_-J63>S*_=AZ7UJX!6-WE/#NC>>DAZ[7$Y9C
MO'%]92%-3F5P4?V6I%TT:F+9=FEY%AU)%M$LZ<01&TF:I1&S;F4,B:7&*MP!
MP[.E$Z?9X(AAM?G6=*)6+J(HK
1U!22-.)4
M;EDNO/M&R!-U-RQB8'HJL?2:)GPI6S=EJ"53L^J)*G'4M)9:(PM&(JEA))ED
MHO>O XC 1'NA:Z-0?45GNID(MM&]Q>]!M'-JJ9_B=ZNH%>;:EBM6>*WM_B=
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MNM&**?,X6I7"1!1>5
EUQJ% C-;[^DH
.
M+K*Z#*IFV#M-!4Y17242RR\LR\$=1:U&+-N4J.TA:G6-&+;
ZWG;^DG3GG3L*B#:5
MB8!B(\FT:H3W2R0U[&\!)!EM%YP>2+KF;RPME/*WE&Y.T)L8(/BFB957(+_F
M?&86L
*2L@?BCVE7%'TG+DI8%I&7-()/*
M19*E^>P-Q7QES6(E6=*8??>UY;Q RDT54SF&.&,,(]C[)YKX[I4!@/TZ2CIT
M6JCC2
&SW)-U#4EQ7*,YHF^*&D:O_P0^R
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MXO#6\)@
_,C]])LJOH3M6: BDG\T2W_-I[.^4_"GGW>3\WD>A
MA\4*D3^%?'M1D%?AV_#/"L@G05LI&D=CMH3G@(!+X^B[+*29Y\/3WQ]9 =]/
M6]+F&QE6$M!UPN[*7^X]/UD']/G.#_G,^$OW!;J*_0 (.]R_G,+SVUNJ&*LY
M913Z1O'EXO:8WSK@._D]TQS;MG[RMCK63MY[;5A-'ZN&56O8U^\9MBDGVZG)
MFI=-Z)RV?+8SSDF!8UIAD'-^G<;%BA=L*R^WNHP94U;PW#)1&+ P3_E'%CPK
MAD8N<=-(6.[ \J/_Y0)(GB%/4?V"QY?\S@^5=!EE,(27O*B$>,7R!$&IKNIV
MA55=X$'K'@"LH0- 4D 5!E:][FG'8B%J%#6Y46-",=9?.:"H\K)%##6J5
U:]4TD;4O:[@!MURMX(HE;$G<7B+M6!139(OJV6,A[ !ZW
M[0=1
=EL"F0WT.H*^^]K1-?U>8DEH++W3=+MR
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MU]@J4:V)W#5RU\A=
<=J6B%DS6DA6U9!4H
M607JW/ID#2!9 ^A$"F2BS.-HI41K%E/>]8ABX!L(:BRIW^NH=JY_9T
+UW'TZ*.4/WM^&R%@6 4!)N.))2)9?&!K( 4_
MSUU$"PY=13"E?_$+@RD)X*A$:YT/R9SF,WZG"=&F5=O*"7]8B,H8/J:1^WDT
MH[D)=86)4O5Y0A?3^4R-V%K5?E0RY[)9)!D&,=6VF[8*F7)I<[[2J(2Y(SF@
M=\5CLU3Q_,2%I:=
L@*F?XP.8LCD'I2.F7
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M-X/?863I']9V\,-'EMPLK?/2,[5?;
XP/1ECXR-(TX%4Q\[3-3096
M_?#;3IY!$S*I0F]21I")6'U5%3
W;55-
M,Y1R1,.E/U1BFFT7FQVH:?N8=4F:MD'WL&PRF5;7>:5M6V2L:K9))E7J34KC
M]FTQ\&OHQCQ_[)W'\M^^1R[$61*&X?!?,!;GD09H_GB3(/&.$:VMDZE>/3I,
M($[41&1XMY#J$$NK6NVL.;P.0Q;ZB2W\,$31Y[;LIXMJNJ$YP&1J]K7OLF33
M*2SI4XM,S;8KZ5_9)30?K-N-0G\.O4I\XRK0W" 92@RH7=[-[ZW (F(?0-0T
MU
7^&?S^,523F';5PN3B[!]^G/XMQ6),/Q;M@/B/
M?"$SO%FLZ9)[Y8H+$%DFP' =)3[:_.]B%O#8]OLGWTN7!?QVWRK@H&Y?H3-8
M=I:>?@6PYHY@P3%UT[LD6ZUH_+P+ 1?.0Q;?AB T]1Q%Z+Q7WD%SI9V?R[B<
MPIHNV&@6,_IY1.
SZ-=TV[;
^5YY!Z^D?IC![^4:^);94B[?J[" @*X3=E?^
Q;?+FX/>:W#OA.
M?L\VQZ9AG[RMCK63]UX;5K/&CCFM->SK]PS;?)/)6I=-Z)Q^4;_#_;3"(.<4
MD<9/OQ=[*H\,\;\H*WAJF2@LQ&H;_\B"9\70R-Y)> :DHBI?QY?\S@^5=!EE
M,(27O#"+7K$\05"JJ[I=8547A%]W#P!6%?*]I:E42,'_8[9>Y^%?--@>D H<
MG_3J3( KV&G71A],N."O*'*S)"U;1RB\CT3A9[O2;M@3#?GUQ8FHY^H&,:R>
MA#M*FNL(S3G$L'O7\4=
YH41;!^1R8QF-#DPE6P
DK73*,RSL?H5
$U_Y&/B#X,'^XE
MRCP*,)!OSP#9F:@]TQS;MG[[0#A]K!I65Z+VY&3?<+*FC(>\>>S8IV7,V 41
MD1*6YV$I8TME;&GO8TL'" !) 6\;75R%U8MA3WD?);RR9,P>69B]L)G<$A(]
MB>6[8N5"!OJ1R
1\.HDOR)N
%1'J+)(?84ZD0B8TCS2%Z90%((JGIC>14/EI%
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MC%YWDG
M0?KP%E.W;\R
M/_'S:O W.-*[*$5>U6-!JG\22U=@Z8;L11 \_3]2@^T<50]#B^6GWI.?ECV7
M>4.4P2BNT[I^=:D6-55#RY&*J]@8DHJK)(G#8(;6*R@-0VU]_^&GX?2?GA"U
M
Y]DCAZ'4?O]!=I$=);/%AJF!!=KUI)3VK:]8O%E(F.@U&Q
M-:R"+)O "X\DS6Q;9I=(.E.U0>K9DB)>\-9IVW5PAZ%J/\ ,Z((I!^4*AAN]
MC;17N5Z9U/4:1Y)JMA@B+)'T!N>Z5,K[3A&P;4V[[>289NN[=NO0OU64=Q58
M"4^RDTE-#;(>Q8A8.&ZPN%>=ZQHM2]QW%/=O40]O )*-)+0:3$:O&VK2#).Y
MJ,9B,0<;UKQ3==& /XMYC%#TN=,,G$(^ 3_T6)C>C?)K#54GTO?"5IO ,GSQ
M ;JV)CB@G^+4F7%: AWYEFP0;Y(52Q_^?B@/"0)DQ4L>U%G44Y65K!\8P:[
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M(SJ'&=[1X(D^)_N+6_GA:!>2AT#(5_7C#S-$Q
8"
9;.7K) D^9/2M1%BL>XQ0>Q<_*FL9IR.)$H:&G^&&2Q31T&;"]%7"]G=OI
MDJ:*GRCLRYJY*?.4-%)BMHY]>!A&G?L)[%3E&41U/A).(F8)/@L[3J&%;$_#
M,(.-\2]X_]G'";E9',,6 8$?W@SA
6<_\"
M81W*\+3-L6G8MT_ML\:..>U*'B),UI)YB#LG+RJ["@MQQLIN1@_F)\YD?N)^
M-L\Q;B3SQBH"\^$$;Y;Y8SM ^I.M*%9_B/$P@N-G(A/)AA,PKH^O*ZDD4/"'
MS+2Y1/L="YE9U9*591@A!\#3G<&$$^B5"5RZJ1LNYC9NT2/9%4;3R
(O;)88RK1M=>Q49%W!9'CI4*U?1;+9]_/&1JYT!H
MZ)O[4##&$Q-7_/,7-\@\EBC?J.-)&<_Q,DS+#Y5Y$-$4WX]IBN%8(0\Q3$Z&
M0XV%+,;_/O !XR.^J#GL&%F3_]B]KE6.EY.5-?F;B$R2-?EW@"%K\LN:_&U!
M3];DES7Y;Z]EO! .94SE<&(JIT9O*J7)ZM*2L+>K=K2:KJ$^$/80@X6%+!;6
MDJE0
OOI!IU>&3EO=OB8+\(STOS[7!+\$T-6T:8"8TAQVDQPDQBZ (,
MM;B#!!>(ADH1SJ2FLUWHRGO=L\6=/_>;J,+7.>5OZE1E:==23XO%V&ZL^/>#
M ISI=;GAD@*Z3@':=3KKFQ* X%*/)+F:3.?*#@5OSW2JQ QB5-I]FU%J?S(W
M"ET_\&E:A..%+%7\T(U6#"L+/7C_S!*L,O3S3[]^^O @8]AZ$&DE)]OU&+:3
MI\&T?W$DGY8Q8\H*GELF6!T.>%$9T?2V,3D]A.5'_\L%D#Q#GJ)J]Z<#*=-E
ME,$0WD51DQU#Z84AD14BT+H'@$NB&GL- $D! D<7PG!-*DB_;>1W&5,XG "
MVR*V*60XC@R.D;1]W:JM*7$L2=N2MGM(VYIA$=6^KMV()&Y)W&(2MV:0B7U=
MPZY.Q35.QA-+.(7@5VS#PY)36D%OXVO>:4!\:N5J.#(BKBG\&,2P38D?@?%C
MFQ.)'V'Q8Q-UVB)^;E[A4>S3$_OMA,E5\7^=(B]-)[9:LQF$+/786 8>F5H2
M26(C2;>(5C=44B*I*21-B:.UC:2A**1Y=!G]HJSCZ-%/_"@
J QQ;9M2)C233(KHF$U/%1I(!2#*JNC>DIEH'U!_8.F9N$
QD63IQ)%($AU))NRDMILM#D.9_9A&[N?1C"8,5[E"UVM^\ [-#8OV
MXKIE%J04WI0^.R6J5)4$1Y*I$;NRO5@BJ6%[L4%,M<7VE0/29_^+Q0L6H_;*
M%O'>X3H
>^RQ18NCN<]%>-
MJ#(Z4G <3?2VO4D20^=VT41M.WQ5XN@
4TT;B/=[*E256
$C)!UU6R;3)V:WIQ; JDQG:9NFQRYE^1>.I
2
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M5XG
^\8"?)CNR2N'M+W()W9)?$+8F[
M?LBD1O2Z?3;[0-M#%'N%9&4MB;VWK_0CG!GZX60<[G#J^M3,K^@P8=>DY^$4
M0*E:>EZ2A!QC8%M$
M'AVR
M;=0K^2%H925)=!TANEJU,2312:*[KH'[5&V[:/:-:*Z*1;9;LG.+)Y'@LK-D
M0[U@0_5JV0C*AR31=8/HZA5]D40GB>Z:1C(JT1PI< DN<+6HA;4D<+U%I>"K
M?-W- ^1MW-U5 "3VKC!K.C[KD8CX6^8M=LHU_J >45K-5DJ2TFY :?(#[7]@
M6+N]IFM8[G9):14I[0TJCTM*$X5I=O,#K]?M+9!GF8#==93XV.;Z+F8!3?U'
MMBTOBZ4/=]XJ/J]N7Z$SF$>6GGX%Z,D= ;EB=^R[)%NM:/R\2[^H%+'X-J3Z
MHDKP"UKE58*G^Q5^=W\NXW(*:]#41K.8T<\C.H<9WM'@B3XG^XM;^>%H%Y*'
M0,A7]>,/,T3%RV^^K"W<2M7D/YD;A:X?^)MFY^&VCG*4I4$4?<9NYX?EE,M;
M1VHG=Z8.\F0RUIWIS6N*ZNK8TBXK
20B?YP,
(Q[._@AE0S@3GOQT
MJ61AAN=#-)_[+E-@Z>Z0+ &W40\N[?;: 0/AF;3@6T&E1R9$6W= T;0-^R4I
MU>MQ:MS*67=V 7F'TRAEWWUM.??*_Z)!QA(%E,<$7:B>LJ+/2ABE"L#7S0+@
M&8J7,3PZ.+H!2>-SG4W%\S["[,,H'/W]X>&/W
VK=_<^:CI
M8]6P.M)]44[V+2=KMNV#[F'CP=8:6_80EI
R=-_]HPT(E6=(8#FV:TAYZ
M^65WLJ%W)Y,4<$@!8@6W-*^-R79D0RSP+=N12=KN*VW+=F22MOM*V[*ECB3N
M_A*WX"UU;N[T%)+V*@5!]JV2M:X37:]:D>\
G4=&+(
M:"B!$6LZ1+5DF%O_$#MUB%[7[2@1*S)B05RH+'9W.'Q12$'BU:2',K;Q!@VX
MNTZLFN$0X\H6W"*PH1NJ)GW!K&X33;VNY;7$K(B8U2<."/LU
3X^W6HIX
9-Z(P);I@>;N->BD170QA
N.R61
MU#"2'*)9;8<^#\-;
<6IRP_9*^UH_2J7?F)Q(A9%5\=UR^N)9JZ6
M%-<5BJM<;D%2G*2X:RP\8[MM;X^DN(%1G%ZSSTCK_L57F\1W2V@]XGR\0G"M
M 9^>[+\K5B[HYKS.VE]Q;[RQVG_1I"X^2"25]X;*U>L"_B652RH7GLKUL3F1
M5"ZIO.]4KM:L3- ,E7-=XV\IG04,_O7\QQ]_@!_EY%8T7O@ACY$P8+G%5T=(
M4W>:4Q*:'WHL3.]&>*4AV.H(VYTX_X:^N0\!!Z117/&G)5/>1RO@%,]*EOH!
MC)8H5 FC>$7Q#P]^+=09S%F(:
Y$=>P@L<^2%\:.$_LE"9^PD@67EF-%9FSPH+
M_)4?4OX&C@,:*G/3!$OHXVQBYF9QC#=IZ!5#CI(U<_VY[RI^RE8)49Z6OKM4
M7!HJCS1^AJDH""G^QCQF?V4X5\+_S)\$G0P&3T%I
!_!AF")^
M.MV"ZKNO'5V;W"=*$(4+#,1A\4J)8":\*&(R5A"LK\*0KM>!#W< EHS"Y_-5
M %Q9 O2(004T473KVWRH$D,K^EP4L(!E)L>&!>0!EG$6 $\_G.,<>*'&&4-%
M%&X_4C^@O/- B(T($'?_S$*7/\3K3N&'(EAL#!!;A A3"@3*'GG)C,@M89\N
M:
=)-
Q
&<,R+M+LA5,]GF7<[M(P/%MF*FF7L1--74?++L_EYL8
MMC5=L-$L9O3SB,YABG
*+/R?[J@/&,=D%Y"(63J+@0B;<&R.0H0/Z$W1ZZ
MP,XWO4=VC%'%MD+>$QZQ596WWV4AS8"7,._[%T0'4@#G(1LJXN<]K"F@ZX3=
ME;_<>WZR#NCSG1_R.?*7[@O %*0'H#D\YCDQY;>W\!^K.0X*XV+QY>+VF-\Z
M$$_R>Y/)6'>F)V^K8^WDO=>&U=6QI9U^=7?8
$-P[&F#>,6["'CJ)^!K5"8?$&PS= ' 8AO:V
MK$'(TM'-M=(<1HN+&[1LO"$7$F2#::HYP*U5NZ%8#T_@V\CFW<)_G6XW_=O[
MU@!W_O7]&/K' H8H?M^X8OB09')M.AVNHEZS,NSED1K=IP]+1W..9:@#9"O7
MU #LGX"A&6C>T8PK#YA.\HLJ=:J&Q!V^,:;('HSI46OO@<=;L)HDPZ#
M'!&&S@6Z%B# 6->#T-?=0->FXUQ_BU+&_1'*_Z)!!GK0-L(18P
7
LHSVE=&^,MI71ON>YABOQM3*>-LS\;;:/EA:C;=M
M,J[V/<@(%,@164!2X7C:/X\,%$(.3B1^[:L.Q=7JQMC6)C>/JYV88\TQFHFK
M%4V&/AXF^0EH[1(1N2?+_<#F?LA9H\#QH#!
RC8Y6(=AITO^9=
@)8)VC2#CXB@H$%]X
MB!BGKU)GR>D)Y%1_-
%Z._?[WG_Y\*$
]YLV;=2
6(DFB/*1L7((>H4&253P6)8H.[/[-[CZR,K0G-W9;.>[?4*99V@_RK]S
M8"@8"F=['_@ B8%PM=^!$,I36G'YRH
=6MD(S+C_+
MD.V _)J@.(_L81W0%&VEPQ-M<@8PXKP2^6$CD
>4F]?W9.3-LT!(@V,CO['T*8H_*W_DQ^= ^ B>((7R!BPC
MW @I9*L1[M!(A#>0U<0L!
S&O,$<(C_3..0VK$V<,"C>(*62/%28H.@,-%/H\-R)
MMI.51O;^>CU'C
&8#1>Y;_@FDG[W6->-(TM[LO/>EZ$F7%/,UZ3@HI$8#^.4CD7Q8U3
M/ J"Z&E#8'ET2R?V9,6]M3/6%]Q0\-4E/]5@?1Z;I?E323;C6Y=;._>#%+;1
M[>CC7YR)-+FE3OYF(73M;^/;QEKV!5#[.QL(R.=[^UA]*W[_U>AE#$5)8-ON
M!Z&=C\0;=$B(?CHDY&^SR'N&?Y;I*OCQ_P!02P$"% ,4 " !98!M=>S3U
M+B0/ "U8 $ @ $ :'%Y+3(P,C8P.#(W+FAT;5!+
M 0(4 Q0 ( %E@&UTNEER): ( ,' 0 " 5(/ !H
M<7DM,C R-C X,C
'-D4$L! A0#% @ 66 ;7?4\]FR$"0 #UD !0
M ( !Z!$ &AQ>2TR,#(V,#@R-U]L86(N>&UL4$L! A0#%
M @ 66 ;7?770;('!@ S, !0 ( !GAL &AQ>2TR,#(V
M,#@R-U]P
&UL4$L! A0#% @ 66 ;7
65A
3(W<3(N:'1M4$L%
3!@ % 4 2P$ !9M $!
end
XML
15
hqy-20260827_htm.xml
IDEA: XBRL DOCUMENT
0001428336
2026-08-27
2026-08-27
0001428336
false
8-K
2026-08-27
HEALTHEQUITY, INC.
DE
001-36568
52-2383166
15 West Scenic Pointe Drive
Suite 100
Draper
UT
84020
801
727-1000
false
false
false
false
Common stock, par value $0.0001 per share
HQY
NASDAQ
false